From a corporate governance standpoint I could see Steve Giardino having turned against NWBO after being such a big booster. I could even see him becoming skeptical of the science because arguably, I’d you cannot trust Linda Powers on one thing you cannot trust her on the science but I can rebut that argument by pointing out Linda Liau at UCLA. That rebuttal is why I have averaged down over the years to support the science, recoup my losses and make money despite being at odds with how the firm is run.
But if Mr. Giardino really rejected the science wholesale and adopted a short position he has had ample chance to cash in by closing it out at fire sale prices. Even now he should still be in the black and can close out.
So while I can grasp the bitterness of a long term shareholder who bought and held against the shorts only to get systematically undermined, I cannot see someone who actually went over to the short side staying mad.
Further, if Giardino is mad he missed an opportunity well okay 20 cents is gone and disgruntled longs like me did not take sufficient advantage of it due to our mistrust (but then that price would not have existed but for NWBO’s credibility gap) but he can still get in pretty cheap and reconfirm his original thesis. If he is not man enough to admit the science is good publicly he can give it a rest, but privately and cash in.
I hope that he turns away from this and does the right thing because if NWBO probes out he had every chance to turn things around for himself and I hate to see people miss out. So what if he or for that matter frustrated longs like myself do not make as much money as the management faithful? Everybody still wins and those who believed more and risked more deserve more because they stood to lose more.
But while maybe the FDA will find a way to nerf DCVax-L in a fair universe where patients are the priority it would get commercialized and DCVax Direct to follow in 6 or 10 years (if success on L allows adequate funding).
News 
Market Data 
Discover 
AI
